Managing multiple myeloma in elderly patients
| Autor: | Evan Diamond, Heather Landau, Oscar B Lahoud |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
Pediatrics medicine.medical_specialty Population Article 03 medical and health sciences 0302 clinical medicine Older patients Recurrence Geriatric population Antineoplastic Combined Chemotherapy Protocols medicine Animals Humans Intensive care medicine education Geriatric Assessment Multiple myeloma Aged Aged 80 and over Polypharmacy education.field_of_study business.industry Age Factors Disease Management Hematology Plasma cell neoplasm Prognosis Tailored treatment medicine.disease Combined Modality Therapy Clinical trial Treatment Outcome Oncology 030220 oncology & carcinogenesis Multiple Myeloma business 030215 immunology |
| Zdroj: | Leuk Lymphoma |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | Multiple myeloma (MM) is a plasma cell neoplasm that affects elderly individuals with two-thirds of patients over 65 years at diagnosis. However, data available are derived from clinical trials conducted in younger patients. Fewer studies investigated treatment options in the elderly. This review summarizes the clinical outcomes and toxicities associated with therapeutic regimens in older patients including doublet, triplet and high dose therapyin newly diagnosed patients and relapsed patients with MM. We highlight the importance of an approach tailored to individuals, incorporates the geriatric frailty assessment, considers comorbiditiess and commits to early recognition and management of toxicities ranging from myelosuppression to polypharmacy. To date, no trial has prospectively investigated a tailored treatment paradigm in older patients based on frailty and/or comorbidities. As the population ages, the proportion of MM patients with advanced age will grow. Studies are indicated to determine optimal treatment approaches in this increasingly heterogeneous geriatric population. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|